Studies of Left Ventricular Dysfunction (SOLVD)
This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00000516
First received: October 27, 1999
Last updated: April 26, 2012
Last verified: April 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To determine if enalapril treatment of left ventricular dysfunction (LVD) due to ischemic or hypertensive heart disease led to reduced mortality and morbidity in symptomatic and asymptomatic patients. There were a Prevention Trial, a Treatment Trial, and a registry.
Condition | Intervention | Phase |
---|---|---|
Cardiovascular Diseases Coronary Disease Heart Diseases Heart Failure Hypertension Myocardial Ischemia |
Drug: enalapril |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Masking: Double-Blind Primary Purpose: Prevention |
Resource links provided by NLM:
MedlinePlus related topics:
Coronary Artery Disease
Heart Diseases
Heart Failure
High Blood Pressure
U.S. FDA Resources
Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):
Eligibility
Ages Eligible for Study: | 21 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Men and women, ages 21 to 80. Subjects were asymptomatic or symptomatic and had ejection fractions equal to or below 35 percent.
Contacts and Locations
More Information
Publications:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on February 24, 2013
Publications:
ClinicalTrials.gov Identifier: | NCT00000516 History of Changes |
Other Study ID Numbers: | 35 |
Study First Received: | October 27, 1999 |
Last Updated: | April 26, 2012 |
Health Authority: | United States: Federal Government |
Additional relevant MeSH terms:
Cardiovascular Diseases Myocardial Ischemia Coronary Artery Disease Coronary Disease Heart Diseases Heart Failure Hypertension Ischemia Ventricular Dysfunction, Left Ventricular Dysfunction Vascular Diseases Arteriosclerosis |
Arterial Occlusive Diseases Pathologic Processes Enalapril Angiotensin-Converting Enzyme Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antihypertensive Agents Cardiovascular Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on February 24, 2013